Accenture Board Insight - Generative AI

Its impact on the modern world has been compared to that of the personal computer and the iPhone. Its adoption is said to imperil millions of jobs and to revolutionise the way our businesses operate.
 
So how are we to handle the way we use Generative AI? And can it really change the way we will live, work and play?

This insight by Criticaleye Partner Accenture looks at five key questions that Board directors should consider in relation to AI.

Key takeaways include:
  • 98 percent of senior executives believe AI will play a key role in their businesses over the next three to five years.
  • Six out of 10 operations have planned to use Chat GPT for learning, with more than half planning to invest in the technology before the end of 2023.




Related Insights

Read, watch & listen to some of the latest thought leadership from our Community.

Click here to download this insight
Embracing the Human-AI Partne...

Singtel faces a rapidly changing environment as geopolitics, customer expectations and AI reshape its business. In discussion with Criticaleye Senior Editor Bridgette Hall, Group Chief People & Sustainability Office...

Click here to download this insight
Reaching New Heights at Guoco...

After four years in the Group CFO role at one of Singapore’s most prominent real estate developers, GuocoLand Group, Andrew Chew talks to Jacob Ambrose Willson about stepping up from regional CFO to Group, managin...

Click here to download this insight
The AI-led HR Revolution at V...

Victrex’s Group HR Director Jilly Atherton has brought together talent planning, leadership development and digital innovation to support a fast-changing global business, using AI where it adds real value without ...


1 2 3 4 5 6 7 8 9 10
Displaying 1 to 3 of 498




Drax Group plc E.ON UK Rolls-Royce Hitachi Solutions Worldpay Workday Google Lightsource bp London Stock Exchange Group FTSE Women Leaders Review Legal & General Eightfold AI Palo Alto Networks Accenture British Land Aldermore Group Salesforce GlaxoSmithKline plc IBM Consulting Concentrix NATS AlixPartners NatWest Group